Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05349643 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT
A Phase 2 study, sponsored by AmMax Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT05349643: Completed Phase 2 study, sponsored by AmMax Bio.
NCT05349643 is a Phase 2 study that has completed, run by AmMax Bio. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05349643, a Phase 2 study, has completed, sponsored by AmMax Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
AMB-051-07 is an open-label, adaptive, dose-ranging study with long-term extension in adults with tenosynovial giant cell tumor
Primary Outcome
Proportion of subjects who achieve an OR (objective response rate \[ORR\]) by central radiology review per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
Interventions
- BIOLOGICAL AMB-05X
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-01-26 |
| Est. Completion | 2024-06-03 |
| Phase | Phase 2 |
What the finished NCT05349643 record still lists
NCT05349643 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which AMB-05X is the first listed.
NCT05349643 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05349643 about?
NCT05349643 is a clinical study titled "A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT". AMB-051-07 is an open-label, adaptive, dose-ranging study with long-term extension in adults with tenosynovial giant cell tumor
What is the current status of trial NCT05349643?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2023-01-26. Estimated completion is 2024-06-03.
What interventions are being tested in trial NCT05349643?
The interventions under investigation include: AMB-05X (BIOLOGICAL).
Who is sponsoring clinical trial NCT05349643?
This trial is sponsored by AmMax Bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05349643's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI